UBS Group
IART icon

UBS Group’s Integra LifeSciences IART Stock Holding History

UBS Group’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-55,000
Closed -$2.26M – 9677
2023
Q2 		$2.26M Sell
55,000
-53,000
-49% -$2.55M ﹤0.01% 3405
2023
Q1 		$6.2M Buy
+108,000
New +$6.09M ﹤0.01% 2314

Other funds holding IART

Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Access Investment Management
Access Investment Management Atlanta, Georgia $412M AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Leeward Investments
Leeward Investments Boston, Massachusetts $1.98B AUM 28.98% 1-Year Est. Return

UBS Group's IART Position: Q3 2026 in Review

UBS Group increased its Integra LifeSciences (IART) stake by 16% in Q3 2026, buying an estimated $376K and bringing the position to 160,086 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #4788.

UBS Group first reported a position in IART in Q4 2014 and has held it in 48 quarters since. The position peaked at $5.08M in Q4 2025. 142 funds tracked by Wall St. Rank hold IART as of Q3 2026.

  • UBS Group held 160,086 shares of Integra LifeSciences worth $2.61M as of Q3 2026.
  • UBS Group bought 21,766 Integra LifeSciences shares in Q3 2026, an estimated $376K.
  • Integra LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4788 holding.
  • UBS Group first reported a position in Integra LifeSciences in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's Integra LifeSciences position peaked at $5.08M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.